Navigation Links
Chesley Files Class Action Against DePuy Orthopaedics
Date:11/4/2010

CINCINNATI, Nov. 4, 2010 /PRNewswire/ -- Stanley M. Chesley of the Cincinnati, Ohio-based law firm of Waite, Schneider, Bayless & Chesley Co., L.P.A. earlier today filed a major class action lawsuit against DePuy Orthopaedics, Inc. and Johnson and Johnson (NYSE: JNJ).

DePuy and Johnson and Johnson recently recalled over 90,000 ASR XL Acetabular hip replacement Systems. The system has an unacceptable failure rate causing patients to undergo hip replacement surgery.

DePuy and Johnson and Johnson notified Chesley's client Carolyn Pearcy that she has a recalled ASR XL Acetabular hip system and advised her, similar to other recipients, to undergo a series of tests. Pearcy believes that her recalled hip was the probable cause of her persistent and excruciating pain.

In her action Pearcy seeks court supervised medical monitoring. The goal is to ensure that every recipient receives without cost necessary medical tests. According to Chesley, "DePuy refuses to accept fundamental financial responsibility. It wants patients and their insurance companies to pay for medical tests required because of DePuy's bad hips."

Pearcy also is seeking damages including punitive damages. Chesley commented that "DePuy and J&J were on notice of the defective system, yet continued to manufacture, market and sell it to innocent victims."

For more than 40 years, Stanley M. Chesley and Waite, Schneider, Bayless & Chesley Co., L.P.A. have represented individuals from across the United States in a variety of personal injury, breach of contract, fraud, and negligence claims, including complex product liability cases, toxic exposure, and dangerous prescription drugs.  More information on the firm is found at http://www.wsbclaw.com.

CONTACT:   Stanley M. Chesley or Terrence L. Goodman at (513) 621-0267


'/>"/>
SOURCE Stanley Chesley of Waite, Schneider, Bayless & Chesley Co., L.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Chesley Files Federal Zicam Lawsuits
2. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
5. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
8. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
9. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... , April 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... management presentation at the Deutsche Bank 41 st Annual ... p.m. EDT. You are invited to listen to ... or access it directly at http://edge.media-server.com/m/p/mr4uxgas . A ... after conclusion of the live event and accessible at the ...
(Date:4/26/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... is projected to grow at a CAGR of 10.38% ... a technique that involves measurement and analysis of DNA ... in biochemical pathways. The aim of performing these tests ...
(Date:4/26/2016)... 26, 2016 Bayer AG has ... taxes, depreciation and amortization. The earnings are the result ... best-selling drugs Xarelto and Eylea, drugs Bayer is banking ... patent expiration date was extended by four years this ... is expected to reach a value of USD ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... ... of a new CDISC standard, Clinical Trial Registry (CTR) XML. Clinical trial ... standard will make it possible to build applications that generate submissions for ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... and the Campaign for Tobacco-Free Kids, a leading force in the fight to ... federal, state and local policies that can help reduce tobacco use. The initiative ...
(Date:4/28/2016)... ... 2016 , ... In 2011, TIME magazine named Herr the “Leader of the ... that marries human physiology with electromechanics. He continues that work as Director of the ... BionX , a leader in the field of prosthetic devices. , After a ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® Citicoline ... 2016. , Nominated in the Healthy Ageing category, Cognizin® is being considered for ... Healthy Ageing division can include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients ...
(Date:4/28/2016)... ... , ... USA Medical Card reminds us that May is National Stroke Awareness Month. According ... cause of death in the United States; someone has one every 40 seconds. Annually, ... under 65 years old. A stroke is when blood flow to the brain is ...
Breaking Medicine News(10 mins):